Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson to buy Aragon Pharmaceuticals for $1bn
As per the acquisition agreeement, an upfront cash payment of $650m in addition to $350m as contingent payments on achieving predetermined milestones will be paid by J&J. Boosting
As per the acquisition agreeement, an upfront cash payment of $650m in addition to $350m as contingent payments on achieving predetermined milestones will be paid by J&J. Boosting
Activartis has developed dendritic cell-based technology for individualized tumor therapy, while clinical development for glioblastoma, an incurable disease, is at an advanced stage. AOP Orphan CEO Rudolf Widmann
In the course of transitioning the sales force from a contract sales organization to an in-house sales team, PuraCap will deploy StayinFront TouchRx, a mobile CRM, for its
Delivering benefits to patients, health care professionals, payers and the pharma industry, Mendor Balance helps in sharing the blood glucose monitoring results of the patients with their caregiver
The investment is intended to form a new packaging facility prior to the launch of multiple new Eisai products. Located adjacent to the currently operating facility, the new
Commenting on further clearances, Roselabs Biosciences director Zameer Agarwal was quoted by The Hindu as saying that Roselabs is awaiting regulatory approvals from 35-40 countries. A drug delivery
The Dietary Supplement Label Database provides the information related to the supplement facts panel that lists the dietary supplements’ contents and other added ingredients such as fillers, binders,
A platform capable of isolating and analyzing EECs has been set up by NGM to recognize novel secreted peptide hormones that are potentially linked to the metabolic effects
Canada health minister Leona Aglukkaq said that millions of Canadians rely on drugs to maintain and improve their health and vague labeling carries some risks. The government will
The IND acceptance will allow the company to advance the development of TX12-004HR for vulvar and vaginal atrophy (VVA) into clinical trials. VVA is a thinning of the